Compagnie Lombard Odier SCmA Buys 16,611 Shares of Zoetis Inc. $ZTS

Compagnie Lombard Odier SCmA boosted its stake in Zoetis Inc. (NYSE:ZTS) by 1,661.1% during the third quarter, Holdings Channel reports. The institutional investor owned 17,611 shares of the company’s stock after buying an additional 16,611 shares during the period. Compagnie Lombard Odier SCmA’s holdings in Zoetis were worth $2,577,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the stock. Wealthfront Advisers LLC boosted its holdings in shares of Zoetis by 54.3% during the third quarter. Wealthfront Advisers LLC now owns 37,220 shares of the company’s stock worth $5,446,000 after acquiring an additional 13,097 shares during the period. AlTi Global Inc. lifted its holdings in Zoetis by 40.1% during the 3rd quarter. AlTi Global Inc. now owns 5,514 shares of the company’s stock worth $806,000 after purchasing an additional 1,577 shares during the last quarter. Candriam S.C.A. boosted its stake in Zoetis by 31.9% in the 3rd quarter. Candriam S.C.A. now owns 784,345 shares of the company’s stock valued at $114,765,000 after purchasing an additional 189,505 shares during the period. AdvisorShares Investments LLC grew its holdings in Zoetis by 12.8% in the 3rd quarter. AdvisorShares Investments LLC now owns 3,165 shares of the company’s stock valued at $463,000 after buying an additional 360 shares in the last quarter. Finally, German American Bancorp Inc. grew its holdings in Zoetis by 2.3% in the 3rd quarter. German American Bancorp Inc. now owns 21,815 shares of the company’s stock valued at $3,192,000 after buying an additional 490 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ZTS. KeyCorp started coverage on shares of Zoetis in a research report on Thursday, November 20th. They issued a “sector weight” rating for the company. BTIG Research reissued a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Stifel Nicolaus dropped their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Finally, HSBC set a $140.00 price target on Zoetis in a research report on Wednesday, December 10th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average price target of $152.45.

Zoetis Stock Performance

NYSE ZTS opened at $127.28 on Tuesday. The firm’s 50 day simple moving average is $123.96 and its 200 day simple moving average is $136.01. The firm has a market capitalization of $56.09 billion, a price-to-earnings ratio of 21.43, a P/E/G ratio of 2.20 and a beta of 0.96. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.00.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.